CD95 maintains the stem‐like and nonclassical EMT programs of GBM,125 and a phase I clinical trial (NCT02853565) in newly diagnosed Asian patients showed that asunercept (which selectively binds to CD95 ligand (CD95L) and disrupts CD95/CD95L signaling) added to standard radiotherapy/TMZ was safe and well tolerated, with encouraging efficacy when administered at 400 mg/week.237. The gene discussed is FASLG; the disease is glioblastoma.